Miraqules at TechCrunch Disrupt 2025: Revolutionizing Blood Clotting

A Biotech Startup Inspired by a Personal Tragedy

Sabir Hossain, the co-founder and CEO of Miraqules, harbored a long-held ambition to emulate his father as an entrepreneur. However, he didn't anticipate establishing a biotechnology firm centered around an innovation that could have potentially aided his father following a life-threatening incident resulting in severe blood loss.

Revolutionary Blood Clotting Technology

Based in Bengaluru, Miraqules has engineered a nanotechnology, delivered in powder form, that replicates the function of blood clotting proteins. This innovative powder swiftly generates fibrous structures at ambient temperature.

These structures exhibit a high volume-to-ratio characteristic, enabling rapid absorption of blood upon application.

Instant Feedback and Rapid Hemostasis

“The product provides immediate, visible results,” Hossain explained to TechCrunch. “When applied to a bleeding wound, the hemorrhage is halted. The entire process occurs within a minute or two.”

TechCrunch Disrupt 2025 Finalist

Miraqules has been selected as a Top 20 Startup Battlefield finalist and will showcase its technology at TechCrunch Disrupt 2025 in San Francisco this week.

Serendipitous Discovery

Hossain described the development of the technology as largely accidental.

His graduate studies in biomedical engineering led him to a research laboratory specializing in biomaterials, where he initially assisted a doctoral student.

Early Research Challenges

“I wasn’t particularly successful in that role,” Hossain admitted. “The student was focused on creating 3D structures to promote bone tissue growth and regeneration. However, my attempts to synthesize the material consistently resulted in its disintegration.”

A Fortuitous Turn of Events

He then processed the fragmented particles into a powder and presented it to a team researching blood clotting, who were facing difficulties with solution mixing. The powder proved remarkably effective.

“It induced complete blood coagulation in approximately five to ten seconds. I immediately informed my professor, and we began investigating the underlying mechanisms,” Hossain stated. “This led to a novel process of combining readily available materials into a nanomaterial that mimics natural blood clotting proteins.”

From Lab to Market

Hossain collaborated with his childhood friend, Mubeen Midda, to translate the technology from the laboratory into a viable product, prioritizing resourcefulness and minimal funding.

The company has since secured 11 patents across seven countries, including India, the United States, and Israel.

Pilot Programs and Regulatory Approvals

Miraqules’ technology is currently undergoing trials in an Indian trauma care center. The company anticipates receiving regulatory approval in India within the coming months.

Furthermore, they are on schedule to obtain clearance from the U.S. Food and Drug Administration by 2026.

Proactive FDA Engagement

“From the outset, we proactively engaged with the U.S. FDA through their pre-submission process. Seeking their guidance on necessary steps for product approval proved invaluable,” Hossain noted.

Lean Startup Funding

The company has achieved these milestones with less than $700,000 in funding, primarily sourced from grants.

Future Expansion and Partnerships

Miraqules plans to expand deployment and pilot programs in the coming year. They have already garnered interest from ten hospital networks in India and the Israeli Defense Forces.

To gain insights directly from the Miraqules team, witness numerous pitches, participate in enriching workshops, and forge connections that drive business outcomes, visit this link to learn more about this year’s Disrupt, taking place October 27 to 29 in San Francisco.